eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2023-09-30 16 3 1701 1706 10.13005/bpj/2748 52352 article Aktsar Roskiana Ahamd 1 Abd. Malik 1 Virsa Handayani 1 Laboratory of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Muslim Indonesia, Makassar/Indonesia This study examined the future of Mahoni seed as an aspirant drug for treating diabetes. Mahogany seeds were washed using n-hexane solvent and followed by ethanol solvent. Extracts were measured using a standard spectrophotometric plate reader with acarbose (Glucobayâ). Glucose tolerance was tested in alloxan-challenged mice. The results indicated that the extract had potency against a-glucosidases inhibited through a non-competitive mechanism. The IC₅₀ value of the extract is 4.7 μg/ml, which was lower than 5.7 μg/ml for acarbose and has less activity on glucose tolerance at doses of 120 and 240 mg/kg. As a conclution, purified mahogany seed extract got the ability to be developed as a new antidiabetic drug candidate. https://biomedpharmajournal.org/vol16no3/in-vivo-and-in-vitro-antidiabetic-assay-of-purified-mahoni-seeds-extract-swietenia-mahagoni-l-jacq/ Antidiabetic Mahoni Seeds Purified Extract (Swietenia mahagoni (l.) Jacq)